Ideaya Biosciences Inc (IDYA) - Net Assets
Based on the latest financial reports, Ideaya Biosciences Inc (IDYA) has net assets worth $937.27 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.03 Billion) and total liabilities ($93.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IDYA intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $937.27 Million |
| % of Total Assets | 90.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | 239.27% |
| 10-Year Change | N/A |
| Growth Volatility | 35.23 |
Ideaya Biosciences Inc - Net Assets Trend (2017–2025)
This chart illustrates how Ideaya Biosciences Inc's net assets have evolved over time, based on quarterly financial data. See Ideaya Biosciences Inc (IDYA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Ideaya Biosciences Inc (2017–2025)
The table below shows the annual net assets of Ideaya Biosciences Inc from 2017 to 2025. For live valuation and market cap data, see IDYA company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.02 Billion | -3.42% |
| 2024-12-31 | $1.06 Billion | +70.53% |
| 2023-12-31 | $621.09 Million | +77.73% |
| 2022-12-31 | $349.45 Million | +15.90% |
| 2021-12-31 | $301.51 Million | +52.07% |
| 2020-12-31 | $198.27 Million | +97.48% |
| 2019-12-31 | $100.40 Million | +305.12% |
| 2018-12-31 | $-48.95 Million | -211.00% |
| 2017-12-31 | $-15.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ideaya Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 72036900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.00% |
| Other Comprehensive Income | $2.27 Million | 0.22% |
| Other Components | $1.76 Billion | 171.78% |
| Total Equity | $1.02 Billion | 100.00% |
Ideaya Biosciences Inc Competitors by Market Cap
The table below lists competitors of Ideaya Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aerospace Auto
SHG:600151
|
$2.47 Billion |
|
Shandong Linuo Technical Glass Co.Ltd.
SHE:301188
|
$2.47 Billion |
|
Viva Energy Group Ltd
AU:VEA
|
$2.47 Billion |
|
Clas Ohlson AB (publ)
ST:CLAS-B
|
$2.47 Billion |
|
Krungthai Card Public Company Limited
BK:KTC-R
|
$2.47 Billion |
|
Krungthai Card PCL
BK:KTC
|
$2.47 Billion |
|
Levi Strauss & Co Class A
NYSE:LEVI
|
$2.47 Billion |
|
CESC Limited
NSE:CESC
|
$2.47 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ideaya Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,059,147,000 to 1,022,934,000, a change of -36,213,000 (-3.4%).
- Net loss of 113,698,000 reduced equity.
- New share issuances of 24,855,000 increased equity.
- Other comprehensive income increased equity by 1,455,000.
- Other factors increased equity by 51,175,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-113.70 Million | -11.11% |
| Share Issuances | $24.86 Million | +2.43% |
| Other Comprehensive Income | $1.46 Million | +0.14% |
| Other Changes | $51.17 Million | +5.0% |
| Total Change | $- | -3.42% |
Book Value vs Market Value Analysis
This analysis compares Ideaya Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.64x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-1.11 | $30.57 | x |
| 2018-12-31 | $-3.44 | $30.57 | x |
| 2019-12-31 | $4.96 | $30.57 | x |
| 2020-12-31 | $8.02 | $30.57 | x |
| 2021-12-31 | $8.55 | $30.57 | x |
| 2022-12-31 | $8.43 | $30.57 | x |
| 2023-12-31 | $10.80 | $30.57 | x |
| 2024-12-31 | $12.97 | $30.57 | x |
| 2025-12-31 | $11.56 | $30.57 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ideaya Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -51.99%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.08x
- Recent ROE (-11.11%) is above the historical average (-15.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.29 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.45 Million |
| 2019 | -38.29% | 0.00% | 0.00x | 1.13x | $-48.48 Million |
| 2020 | -16.27% | -165.14% | 0.07x | 1.50x | $-52.09 Million |
| 2021 | -15.76% | -170.11% | 0.07x | 1.26x | $-77.68 Million |
| 2022 | -15.68% | -107.61% | 0.13x | 1.11x | $-89.75 Million |
| 2023 | -18.19% | -483.05% | 0.04x | 1.05x | $-175.07 Million |
| 2024 | -25.91% | -3921.10% | 0.01x | 1.06x | $-380.39 Million |
| 2025 | -11.11% | -51.99% | 0.20x | 1.08x | $-215.99 Million |
Industry Comparison
This section compares Ideaya Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ideaya Biosciences Inc (IDYA) | $937.27 Million | 0.00% | 0.10x | $2.47 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and … Read more